Stay updated on Guselkumab in Active PsA: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page.

Latest updates to the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page
- Check5 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site as revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check12 days agoChange DetectedThe ClinicalTrials.gov page now displays the completed guselkumab study record, including its design, eligibility criteria, outcomes, and record history, instead of a 403 error screen.SummaryDifference80%

- Check19 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH-wide notice about terminology changes appears above the 403 Forbidden page, and the site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe ClinicalTrials.gov study page remains a 403 Forbidden error, while the displayed site revision changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content. This shows the page is currently blocked from access.SummaryDifference20%

Stay in the know with updates to Guselkumab in Active PsA: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guselkumab in Active PsA: Efficacy & Safety Clinical Trial page.